TAX-TORC: A Phase I multi-centre trial of the combination of AZD2014 (dual TORC1 and TORC2 inhibitor) and weekly paclitaxel in patients with solid tumours

Trial Profile

TAX-TORC: A Phase I multi-centre trial of the combination of AZD2014 (dual TORC1 and TORC2 inhibitor) and weekly paclitaxel in patients with solid tumours

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Vistusertib (Primary) ; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms TAX-TORC
  • Most Recent Events

    • 06 Jun 2017 Results from dose-escalation followed by dose-expansion part of the study in patients with ovarian cancer, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 11 Oct 2016 Results (n=20) presented at the 41st European Society for Medical Oncology Congress
    • 05 Mar 2016 Accrual to date is 62% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top